Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.48 |
| ▸ | CLPP | Q16740 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAT2A | P31153 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 5/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 4/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526092 | 0.89 | YTHDC1 (0.45) | YTHDC1NPC1CDK1PRKCA | |
| SCHEMBL4531049 | 0.87 | HPGD (0.46) | YTHDC1NPC1 | |
| SCHEMBL4521275 | 0.86 | ALDH1A3 (0.44) | YTHDC1MAT2ACDK1 | |
| SCHEMBL4505408 | 0.86 | YTHDC1 (0.46) | YTHDC1NPC1 | |
| SCHEMBL4520999 | 0.85 | NPC1 (0.44) | YTHDC1NPC1RXFP1 | |
| SCHEMBL4511448 | 0.84 | HSD17B10 (0.47) | YTHDC1RXFP1 | |
| SCHEMBL4521578 | 0.84 | TP53 (0.42) | YTHDC1MAT2ACDK1PRKCA | |
| SCHEMBL4509737 | 0.82 | CNR1 (0.38) | YTHDC1NPC1MAT2ARXFP1 | |
| SCHEMBL4520072 | 0.81 | MAT2A (0.38) | YTHDC1NPC1MAT2ARXFP1 | |
| SCHEMBL4525433 | 0.80 | POLB (0.37) | YTHDC1NPC1MAT2ACDK1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | YTHDC1 4699/4885CLPP 4798/4885NPC1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.